Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV). We also have additional preclinical stage programs, including the Middle East Respiratory Syndrome coronavirus (MERS). Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Type
Public
HQ
Gaithersburg, US
Founded
1987
Size (employees)
355 (est)-19%
Novavax was founded in 1987 and is headquartered in Gaithersburg, US

Novavax Office Locations

Novavax has offices in Gaithersburg, Rockville, Uppsala
Gaithersburg, US (HQ)
20 Firstfield Rd
Uppsala, SE
109 Kungsgatan
Rockville, US
9920 Belward Campus Dr

Novavax Metrics

Novavax Financial Metrics

Revenue (2016)

$15.4 m

Revenue growth (2015-16), %

(58%)

Net income (2016)

($280 m)

Market capitalization (21-Mar-2017)

$348.5 m

Closing share price (21-Mar-2017)

$1.3

Cash (31-Dec-2016)

$144.4 m
Novavax's current market capitalization is $348.5 m.
Novavax's revenue was reported to be $15.4 m in FY, 2016 which is a 57.6% decrease from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$343 k$14.7 m$22.1 m$20.9 m$30.7 m$36.3 m$15.4 m

Revenue growth, %

4182%50%(5%)47%18%(58%)

R&D expense

$50.3 m$79.4 m$162.6 m$237.9 m

General and administrative expense

$14.8 m$19.9 m$30.8 m$46.5 m

Operating expense total

$73.3 m$114.4 m$193.5 m$284.5 m

EBIT

($83.7 m)($157.2 m)($269.1 m)

EBIT margin, %

(273%)(434%)(1753%)

Interest expense

$9 k$9 k$32 k($160 k)($157 k)($241 k)($13 m)

Interest income

$187 k

Income tax expense

$450 k$412 k$25 k

Net Income

($52 m)($82.9 m)($156.9 m)($280 m)
Y, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

$38.8 m$8.1 m$14.1 m$17.4 m$119.5 m$32.3 m$93.1 m$144.4 m

Inventories

$46.3 m$57.1 m

Current Assets

$145 m$188.2 m$287.3 m$287.8 m

PP&E

$14.3 m$19.7 m$32.3 m$40.2 m

Goodwill

$59.5 m$54.6 m$53.1 m$51.7 m

Total Assets

$235.9 m$276 m$386 m$394.3 m

Accounts Payable

$33.9 m$51.5 m

Current Liabilities

$18.9 m$34.1 m$76.5 m$66.4 m

Additional Paid-in Capital

$612.9 m$729.4 m$951.6 m$936 m

Retained Earnings

($410.1 m)($493.1 m)($650 m)($930 m)

Total Equity

$203.2 m$229.6 m$292.7 m($5.5 m)

Financial Leverage

1.2 x1.2 x1.3 x-71.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($52 m)($82.9 m)($156.9 m)($280 m)

Depreciation and Amortization

$2.6 m$4.4 m$6 m$8.5 m

Accounts Receivable

($18.3 m)

Inventories

($33.8 m)$82.3 m$42 m

Accounts Payable

($2.3 m)($104.1 m)$12 m

Cash From Operating Activities

($45.4 m)($87.1 m)$60.8 m($255.5 m)

Capital Expenditures

($5.8 m)($7.3 m)($18.3 m)($18.2 m)

Cash From Investing Activities

$16.4 m($129.8 m)($21.3 m)$28 m

Short-term Borrowings

($671 k)

Cash From Financing Activities

$131 m$109.7 m$208.3 m$279 m

Free Cash Flow

($51.1 m)($94.4 m)$42.5 m($273.7 m)

Novavax Market Value History

Novavax Job Categories

Novavax Median Salaries

Source: 30 public H-1B filings from Novavax

Novavax Online Presence

Novavax Company Life

You may also be interested in